1.Guideline for the Surgical Management of Locally Invasive Differentiated Thyroid Cancer From the Korean Society of Head and Neck Surgery
Jun-Ook PARK ; Joo Hyun KIM ; Young Hoon JOO ; Sang-Yeon KIM ; Geun-Jeon KIM ; Hyun Bum KIM ; Dong-Hyun LEE ; Hyun Jun HONG ; Young Min PARK ; Eun-Jae CHUNG ; Yong Bae JI ; Kyoung Ho OH ; Hyoung Shin LEE ; Dong Kun LEE ; Ki Nam PARK ; Myung Jin BAN ; Bo Hae KIM ; Do Hun KIM ; Jae-Keun CHO ; Dong Bin AHN ; Min-Su KIM ; Jun Girl SEOK ; Jeon Yeob JANG ; Hyo Geun CHOI ; Hee Jin KIM ; Sung Joon PARK ; Eun Kyung JUNG ; Yeon Soo KIM ; Yong Tae HONG ; Young Chan LEE ; Ho-Ryun WON ; Sung-Chan SHIN ; Seung-Kuk BAEK ; Soon Young KWON
Clinical and Experimental Otorhinolaryngology 2023;16(1):1-19
The aim of this study was to develop evidence-based recommendations for determining the surgical extent in patients with locally invasive differentiated thyroid cancer (DTC). Locally invasive DTC with gross extrathyroidal extension invading surrounding anatomical structures may lead to several functional deficits and poor oncological outcomes. At present, the optimal extent of surgery in locally invasive DTC remains a matter of debate, and there are no adequate guidelines. On October 8, 2021, four experts searched the PubMed, Embase, and Cochrane Library databases; the identified papers were reviewed by 39 experts in thyroid and head and neck surgery. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the quality of evidence, and to develop and report recommendations. The strength of a recommendation reflects the confidence of a guideline panel that the desirable effects of an intervention outweigh any undesirable effects, across all patients for whom the recommendation is applicable. After completing the draft guidelines, Delphi questionnaires were completed by members of the Korean Society of Head and Neck Surgery. Twenty-seven evidence-based recommendations were made for several factors, including the preoperative workup; surgical extent of thyroidectomy; surgery for cancer invading the strap muscles, recurrent laryngeal nerve, laryngeal framework, trachea, or esophagus; and surgery for patients with central and lateral cervical lymph node involvement. Evidence-based guidelines were devised to help clinicians make safer and more efficient clinical decisions for the optimal surgical treatment of patients with locally invasive DTC.
2.Evaluating Diagnostic Tests for Helicobacter pylori Infection Without a Reference Standard: Use of Latent Class Analysis
Dong Wook JEKARL ; Hyunyu CHOI ; Ji Yeon KIM ; Seungok LEE ; Tae Geun GWEON ; Hae Kyung LEE ; Yonggoo KIM
Annals of Laboratory Medicine 2020;40(1):68-71
Evaluation of diagnostic tests requires reference standards, which are often unavailable. Latent class analysis (LCA) can be used to evaluate diagnostic tests without reference standards, using a combination of observed and estimated results. Conditionally independent diagnostic tests for Helicobacter pylori infection are required. We used LCA to construct a reference standard and evaluate the capability of non-invasive tests (stool antigen test and serum antibody test) to diagnose H. pylori infection compared with the conventional method, where histology is the reference standard. A total of 96 healthy subjects with endoscopy histology results were enrolled from January to July 2016. Sensitivity and specificity were determined for the LCA approach (i.e., using a combination of three tests as the reference standard) and the conventional method. When LCA was used, sensitivity and specificity were 83.8% and 99.4% for histology, 80.0% and 81.9% for the stool antigen test, and 63.6% and 89.3% for the serum antibody test, respectively. When the conventional method was used, sensitivity and specificity were 75.8% and 71.1% for the stool antigen test and 77.7% and 60.7% for the serum antibody test, respectively. LCA can be applied to evaluate diagnostic tests that lack a reference standard.
3.Comparative Evaluation of Hormones and Hormone-Like Molecule in Lineage Specification of Human Induced Pluripotent Stem Cells
Seon A CHOI ; Ju Hyun AN ; Seung Hwan LEE ; Geun Hui LEE ; Hae Jun YANG ; Pil Soo JEONG ; Jae Jin CHA ; Sanghoon LEE ; Young Ho PARK ; Bong Seok SONG ; Bo Woong SIM ; Young Hyun KIM ; Ji Su KIM ; Yeung Bae JIN ; Jae Won HUH ; Sang Rae LEE ; Jong Hee LEE ; Sun Uk KIM
International Journal of Stem Cells 2019;12(2):240-250
BACKGROUND AND OBJECTIVES: Proficient differentiation of human pluripotent stem cells (hPSCs) into specific lineages is required for applications in regenerative medicine. A growing amount of evidences had implicated hormones and hormone-like molecules as critical regulators of proliferation and lineage specification during in vivo development. Therefore, a deeper understanding of the hormones and hormone-like molecules involved in cell fate decisions is critical for efficient and controlled differentiation of hPSCs into specific lineages. Thus, we functionally and quantitatively compared the effects of diverse hormones (estradiol 17-β (E2), progesterone (P4), and dexamethasone (DM)) and a hormone-like molecule (retinoic acid (RA)) on the regulation of hematopoietic and neural lineage specification. METHODS AND RESULTS: We used 10 nM E2, 3 μM P4, 10 nM DM, and 10 nM RA based on their functional in vivo developmental potential. The sex hormone E2 enhanced functional activity of hematopoietic progenitors compared to P4 and DM, whereas RA impaired hematopoietic differentiation. In addition, E2 increased CD34⁺CD45⁺ cells with progenitor functions, even in the CD43⁻ population, a well-known hemogenic marker. RA exhibited lineage-biased potential, preferentially committing hPSCs toward the neural lineage while restricting the hematopoietic fate decision. CONCLUSIONS: Our findings reveal unique cell fate potentials of E2 and RA treatment and provide valuable differentiation information that is essential for hPSC applications.
Dexamethasone
;
Humans
;
Induced Pluripotent Stem Cells
;
Pluripotent Stem Cells
;
Progesterone
;
Regenerative Medicine
;
Tretinoin
4.Erratum to: The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group.
Do Young KWON ; Seong Beom KOH ; Jae Hyeok LEE ; Hee Kyung PARK ; Han Joon KIM ; Hae Won SHIN ; Jinyoung YOUN ; Kun Woo PARK ; Sun Ah CHOI ; Sang Jin KIM ; Seong Min CHOI ; Ji Yun PARK ; Beom S. JEON ; Ji Young KIM ; Sun Ju CHUNG ; Chong Sik LEE ; Jeong Ho PARK ; Tae Beom AHN ; Won Chan KIM ; Hyun Sook KIM ; Sang Myung CHEON ; Hee Tae KIM ; Jee Young LEE ; Ji Sun KIM ; Eun Joo KIM ; Jong Min KIM ; Kwang Soo LEE ; Joong Seok KIM ; Min Jeong KIM ; Jong Sam BAIK ; Ki Jong PARK ; Hee Jin KIM ; Mee Young PARK ; Ji Hoon KANG ; Sook Kun SONG ; Yong Duk KIM ; Ji Young YUN ; Ho Won LEE ; Hyung Geun OH ; Jinwhan CHO ; In Uk SONG ; Young H. SOHN ; Phil Hyu LEE ; Jae Woo KIM
Journal of Clinical Neurology 2017;13(3):315-315
The original version of this article contained wrong informations of some authors which should be changed.
5.The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group.
Do Young KWON ; Seong Beom KOH ; Jae Hyeok LEE ; Hee Kyung PARK ; Han Joon KIM ; Hae Won SHIN ; Jinyoung YOUN ; Kun Woo PARK ; Sun Ah CHOI ; Sang Jin KIM ; Seong Min CHOI ; Ji Yun PARK ; Beom S JEON ; Ji Young KIM ; Sun Ju CHUNG ; Chong Sik LEE ; Jeong Ho PARK ; Tae Beom AHN ; Won Chan KIM ; Hyun Sook KIM ; Sang Myung CHEON ; Hee Tae KIM ; Jee Young LEE ; Ji Sun KIM ; Eun Joo KIM ; Jong Min KIM ; Kwang Soo LEE ; Joong Seok KIM ; Min Jeong KIM ; Jong Sam BAIK ; Ki Jong PARK ; Hee Jin KIM ; Mee Young PARK ; Ji Hoon KANG ; Sook Kun SONG ; Yong Duk KIM ; Ji Young YUN ; Ho Won LEE ; Hyung Geun OH ; Jinwhan CHO ; In Uk SONG ; Young H SOHN ; Phil Hyu LEE ; Jae Woo KIM
Journal of Clinical Neurology 2016;12(4):393-402
BACKGROUND AND PURPOSE: Nonmotor symptoms (NMS) in Parkinson's disease (PD) have multisystem origins with heterogeneous manifestations that develop throughout the course of PD. NMS are increasingly recognized as having a significant impact on the health-related quality of life (HrQoL). We aimed to determine the NMS presentation according to PD status, and the associations of NMS with other clinical variables and the HrQoL of Korean PD patients. METHODS: We surveyed patients in 37 movement-disorders clinics throughout Korea. In total, 323 PD patients were recruited for assessment of disease severity and duration, NMS, HrQoL, and other clinical variables including demographics, cognition, sleep scale, fatigability, and symptoms. RESULTS: In total, 98.1% of enrolled PD subjects suffered from various kinds of NMS. The prevalence of NMS and scores in each NMS domain were significantly higher in the PD group, and the NMS worsened as the disease progressed. Among clinical variables, disease duration and depressive mood showed significant correlations with all NMS domains (p<0.001). NMS status impacted HrQoL in PD (rS=0.329, p<0.01), and the association patterns differed with the disease stage. CONCLUSIONS: The results of our survey suggest that NMS in PD are not simply isolated symptoms of degenerative disease, but rather exert significant influences throughout the disease course. A novel clinical approach focused on NMS to develop tailored management strategies is warranted to improve the HrQoL in PD patients.
Cognition
;
Demography
;
Humans
;
Korea
;
Movement Disorders*
;
Parkinson Disease*
;
Prevalence
;
Quality of Life*
6.Heterogeneous living donor hepatic fat distribution on MRI chemical shift imaging.
Youngrok CHOI ; Jeong Min LEE ; Nam Joon YI ; Hyeyoung KIM ; Min Su PARK ; Geun HONG ; Tae YOO ; Suk Won SUH ; Hae Won LEE ; Kwang Woong LEE ; Kyung Suk SUH
Annals of Surgical Treatment and Research 2015;89(1):37-42
PURPOSE: We evaluated the heterogeneity of steatosis in living donor livers to determine its regional differences. METHODS: Between June 2011 and February 2012, 81 liver donors were selected. Fat fraction was estimated using magnetic resonance triple-echo chemical shifting gradient imaging in 13 different regions: segment 1 (S1), S2, S3, and each peripheral and deep region of S4, S5, S6, S7, and S8. RESULTS: There were differences (range, 3.2%-5.3%) in fat fractions between each peripheral and deep region of S4, S6, S7, and S8 (P < 0.001, P = 0.004, P < 0.001, and P = 0.006). Fat deposit amount in S1, S2, S3 and deep regions of S4-S8 were significantly different from one another (F [4.003, 58.032] = 8.684, P < 0.001), while there were no differences among the peripheral regions of S4-S8 (F [2.9, 5.3] = 1.3, P = 0.272) by repeated measure analysis of variance method. And regional differences of the amount of fat deposit in the whole liver increased as a peripheral fat fraction of S5 increased (R2 = 0.428, P < 0.001). CONCLUSION: Multifocal fat measurements for the whole liver are needed because a small regional evaluation might not represent the remaining liver completely, especially in patients with severe hepatic steatosis.
Fatty Liver
;
Humans
;
Liver
;
Liver Transplantation
;
Living Donors*
;
Magnetic Resonance Imaging*
;
Population Characteristics
;
Tissue Donors
;
Transplant Donor Site
7.Therapeutic Effects of S-Petasin on Disease Models of Asthma and Peritonitis.
Kyoung Pil LEE ; Saeromi KANG ; Min Soo NOH ; Soo Jin PARK ; Jung Min KIM ; Hae Young CHUNG ; Nam Kyung JE ; Young Geun LEE ; Young Whan CHOI ; Dong Soon IM
Biomolecules & Therapeutics 2015;23(1):45-52
To explore the anti-allergic and anti-inflammatory effects of extracts of Petasites genus, we studied the effects of s-petasin, a major sesquiterpene from Petasites formosanus (a butterbur species) on asthma and peritonitis models. In an ovalbumin-induced mouse asthma model, s-petasin significantly inhibited the accumulations of eosinophils, macrophages, and lymphocytes in bronchoalveolar fluids. S-petasin inhibited the antigen-induced degranulation of beta-hexosamidase but did not inhibit intracellular Ca2+ increase in RBL-2H3 mast cells. S-petasin inhibited the LPS induction of iNOS at the RNA and protein levels in mouse peritoneal macrophages. Furthermore, s-petasin inhibited the production of NO (the product of iNOS) in a concentration-dependent manner in the macrophages. Furthermore, in an LPS-induced mouse model of peritonitis, s-petasin significantly inhibited the accumulation of polymorpho nuclear and mononuclear leukocytes in peritoneal cavity. This study shows that s-petasin in Petasites genus has therapeutic effects on allergic and inflammatory diseases, such as, asthma and peritonitis through degranulation inhibition in mast cells, suppression of iNOS induction and production of NO in macrophages, and suppression of inflammatory cell accumulation.
Animals
;
Asthma*
;
Eosinophils
;
Leukocytes, Mononuclear
;
Lymphocytes
;
Macrophages
;
Macrophages, Peritoneal
;
Mast Cells
;
Mice
;
Peritoneal Cavity
;
Peritonitis*
;
Petasites
;
RNA
8.Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.
Hyeyoung KIM ; Nam Joon YI ; Juyeun LEE ; Joohyun KIM ; Mi Ra MOON ; Jaehong JEONG ; Jeong Moo LEE ; Tae Suk YOU ; Suk Won SUH ; Min Su PARK ; Youngrok CHOI ; Geun HONG ; Hae Won LEE ; Kwang Woong LEE ; Kyung Suk SUH
Clinical and Molecular Hepatology 2014;20(3):291-299
BACKGROUND/AIMS: The dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associated with the conventional fixed dose of 2-3 g/day. We aimed to determine the pharmacokinetics of a reduced dose of MMF and to validate its feasibility in combination with tacrolimus in living-donor liver transplantation (LDLT). METHODS: Two sequential studies were performed in adult LDLT between October 2009 and 2011. First, we performed a prospective pharmacokinetic study in 15 recipients. We measured the area under the curve from 0 to 12 hours (AUC0-12) for mycophenolic acid at postoperative days 7 and 14, and we performed a protocol biopsy before discharge. Second, among 215 recipients, we reviewed 74 patients who were initially administered a reduced dose of MMF (1.0 g/day) with tacrolimus (trough, 8-12 ng/mL during the first month, and 5-8 ng/mL thereafter), with a 1-year follow-up. We performed protocol biopsies at 2 weeks and 1 year post-LDLT. RESULTS: In the first part of study, AUC0-12 was less than 30 mgh/L in 93.3% of cases. In the second, validating study, 41.9% of the recipients needed dose reduction or cessation due to side effects within the first year after LDLT. At 12 months post-LDLT, 17.6% of the recipients were administered a lower dose of MMF (0.5 g/day), and 16.2% needed permanent cessation due to side effects. The 1- and 12-month rejection-free survival rates were 98.6% and 97.3%, respectively. CONCLUSIONS: A reduced dose of MMF was associated with low blood levels compared to the existing recommended therapeutic range. However, reducing the dose of MMF combined with a low level of tacrolimus was feasible clinically, with an excellent short-term outcome in LDLT.
Adult
;
Aged
;
Area Under Curve
;
Drug Therapy, Combination
;
Female
;
Follow-Up Studies
;
Gastrointestinal Diseases/etiology
;
Graft Rejection/prevention & control
;
Humans
;
Immunosuppressive Agents/blood/*pharmacokinetics
;
Leukopenia/etiology
;
Liver/pathology
;
Liver Failure/*therapy
;
*Liver Transplantation
;
Male
;
Middle Aged
;
Mycophenolic Acid/adverse effects/*analogs & derivatives/blood/pharmacokinetics
;
ROC Curve
;
Retrospective Studies
;
Tacrolimus/therapeutic use
;
Tissue Donors
9.Prevalence of Anti-Ganglioside Antibodies and Their Clinical Correlates with Guillain-Barre Syndrome in Korea: A Nationwide Multicenter Study.
Jong Kuk KIM ; Jong Seok BAE ; Dae Seong KIM ; Susumu KUSUNOKI ; Jong Eun KIM ; Ji Soo KIM ; Young Eun PARK ; Ki Jong PARK ; Hyun Seok SONG ; Sun Young KIM ; Jeong Geun LIM ; Nam Hee KIM ; Bum Chun SUH ; Tai Seung NAM ; Min Su PARK ; Young Chul CHOI ; Eun Hee SOHN ; Sang Jun NA ; So Young HUH ; Ohyun KWON ; Su Yun LEE ; Sung Hoon LEE ; Sun Young OH ; Seong Hae JEONG ; Tae Kyeong LEE ; Dong Uk KIM
Journal of Clinical Neurology 2014;10(2):94-100
BACKGROUND AND PURPOSE: No previous studies have investigated the relationship between various anti-ganglioside antibodies and the clinical characteristics of Guillain-Barre syndrome (GBS) in Korea. The aim of this study was to determine the prevalence and types of anti-ganglioside antibodies in Korean GBS patients, and to identify their clinical significance. METHODS: Serum was collected from patients during the acute phase of GBS at 20 university-based hospitals in Korea. The clinical and laboratory findings were reviewed and compared with the detected types of anti-ganglioside antibody. RESULTS: Among 119 patients, 60 were positive for immunoglobulin G (IgG) or immunoglobulin M antibodies against any type of ganglioside (50%). The most frequent type was IgG anti-GM1 antibody (47%), followed by IgG anti-GT1a (38%), IgG anti-GD1a (25%), and IgG anti-GQ1b (8%) antibodies. Anti-GM1-antibody positivity was strongly correlated with the presence of preceding gastrointestinal infection, absence of sensory symptoms or signs, and absence of cranial nerve involvement. Patients with anti-GD1a antibody were younger, predominantly male, and had more facial nerve involvement than the antibody-negative group. Anti-GT1a-antibody positivity was more frequently associated with bulbar weakness and was highly associated with ophthalmoplegia when coupled with the coexisting anti-GQ1b antibody. Despite the presence of clinical features of acute motor axonal neuropathy (AMAN), 68% of anti-GM1- or anti-GD1a-antibody-positive cases of GBS were diagnosed with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) by a single electrophysiological study. CONCLUSIONS: Anti-ganglioside antibodies were frequently found in the serum of Korean GBS patients, and each antibody was correlated strongly with the various clinical manifestations. Nevertheless, without an anti-ganglioside antibody assay, in Korea AMAN is frequently misdiagnosed as AIDP by single electrophysiological studies.
Amantadine
;
Antibodies*
;
Axons
;
Cranial Nerves
;
Facial Nerve
;
Guillain-Barre Syndrome*
;
Humans
;
Immunoglobulin G
;
Immunoglobulin M
;
Korea
;
Male
;
Ophthalmoplegia
;
Prevalence*
10.Erlotinib Induced Trichomegaly of the Eyelashes.
Sang Hoon JEON ; Jeong Seon RYU ; Gwang Seong CHOI ; Jung Soo KIM ; Hea Yoon KWON ; Min Su KIM ; Hae Seong NAM ; Jae Hwa CHO ; Seung Min KWAK ; Hong Lyeol LEE ; Hyun Jung KIM ; Geun Jeong HONG
Tuberculosis and Respiratory Diseases 2013;74(1):37-40
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many patients treated with EGFR TKIs. However trichomegaly of eyelash is rarely reported. Although trichomegaly is not a drug-limiting side effect, it could be troublesome of continuing the treatment because of cosmetic issue or eyeball irritation by long eyelashes. Therefore clinicians are needed to pay attention to this uncommon effect. We herein describe erlotinib induced trichomegaly of eyelashes in a woman with adenocarcinoma of the lung.
Adenocarcinoma
;
Cosmetics
;
Eyelashes
;
Female
;
Humans
;
Lung
;
Lung Neoplasms
;
Physiological Effects of Drugs
;
Protein-Tyrosine Kinases
;
Quinazolines
;
Receptor, Epidermal Growth Factor
;
Erlotinib Hydrochloride

Result Analysis
Print
Save
E-mail